As of June 30, 2025, the Company’s cash, cash equivalents and investments were $274.9 million. The Company expects that its cash, cash equivalents and investments, as of June 30, 2025, will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Sixteen new option listings on July 23rd
- Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
- Zenas BioPharma assumed with an Overweight at Morgan Stanley
- Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
- Zenas BioPharma Announces Board Changes at Annual Meeting